Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis (P4-18.002)

Ahmed Abdelhak; Gabby Joseph; Riley Bove; Bruce Cree; Valerie Block

doi:10.1212/wnl.0000000000215197

June 9, 2026Neurology

Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis (P4-18.002)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to explore the relationship between serum neurofilament light chain levels and mobility measured by step counts in individuals with progressive multiple sclerosis.
Utilized data from a large international cohort of individuals with progressive multiple sclerosis.
Participants took part in a randomized controlled trial, allowing for robust findings on mobility and molecular markers.
Found a significant association between higher serum neurofilament light chain levels and lower step counts, indicating greater neuroaxonal damage.
Data suggests that monitoring sNfL could serve as an important biomarker for mobility in individuals with progressive MS.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial assesses link between serum neurofilament levels and mobility in progressive multiple sclerosis, suggesting new insights for treatment.

Abstract

Assess associations between serum neurofilament light chain (sNfL) levels and step count in a large international cohort of people with progressive multiple sclerosis (MS) who participated in a randomized controlled trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abdelhak et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055bd9 https://doi.org/10.1212/wnl.0000000000215197

View at Publisher

Ask AI

Bookmark

Share

Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis (P4-18.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis (P4-18.002)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading